This is the authors' abstract. We don't add key points for this paper.
Infectious bronchitis virus causes an acute, highly contagious respiratory disease, responsible for significant economic losses to the poultry industry. Amino acid differences in the surface protein, spike (S), in particular the S1 subunit, have been associated with poor cross-protection. Available vaccines give poor cross-protection and rationally designed live attenuated vaccines, based on apathogenic BeauR, could address these. Here, to determine the role of S1 in protection, a series of homologous vaccination trials with rIBVs were conducted. Single vaccinations with chimeric rIBVs induced virus-specific partial protective immunity, characterized by reduction in viral load and serum antibody titers. However, BeauR-M41(S) was the only vaccination to improve the level of protection against clinical signs and the loss of tracheal ciliary activity. Growth characteristics show that all of the rIBVs replicatedin vitroto similar levels. Booster vaccinations and an rIBV with improvedin vivoreplication may improve the levels of protection.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Keep et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: